STOCK TITAN
  1. Home
  2. News
  3. COYA

Coya Therapeutics, Inc. - COYA STOCK NEWS

Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.

Coya Therapeutics, Inc. (symbol: COYA) is a clinical-stage biotechnology company dedicated to pioneering therapies that regulate the function of regulatory T cells (Tregs). The company focuses on developing novel and proprietary medicinal products aimed at modulating Tregs to treat a range of debilitating diseases, including neurodegenerative, autoimmune, and metabolic disorders.

With a strong emphasis on scientific innovation, Coya Therapeutics is engaged in multi-modality Treg therapies designed to address unmet medical needs in these critical areas. By harnessing the power of Tregs, the company aims to restore immune balance and bring new hope to patients suffering from conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

In recent developments, Coya Therapeutics has made significant strides in its research and development programs, advancing its pipeline of therapeutic candidates. The company is currently engaged in multiple clinical trials to evaluate the safety and efficacy of its Treg-targeted treatments. These efforts are supported by a robust financial condition, strategic partnerships, and collaborations with leading research institutions and healthcare organizations.

Coya Therapeutics' commitment to scientific excellence and patient well-being positions it as a key player in the biotechnology sector. Investors and stakeholders can look forward to updates on clinical trial progress, new product developments, and potential market launches that underscore the company's growth trajectory and impact on the healthcare landscape.

Stay tuned to Coya Therapeutics' news releases and financial reports for the latest information on the company's achievements and future directions.

News

Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Rhea-AI Summary
Coya Therapeutics, Inc. (COYA) has successfully obtained constructive feedback and reached alignment with the FDA on key areas involved in the development of COYA 302, a dual-mechanism investigational biologic combination therapy for the treatment of ALS. This significant step paves the way for the submission of the IND application to the FDA in the second quarter of 2024 and the initiation of a well-controlled, double-blind clinical trial of COYA 302 in ALS patients. The company has secured a cash runway into 2026 through recent out-licensing and private placement transactions, positioning it to deliver value to patients and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
News

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) has appointed Secretary Wilbur Ross, former Chairman and Chief Strategy Officer of WL Ross & Co., to its board of directors. The clinical-stage biotechnology company aims to leverage Secretary Ross's extensive experience in business and investment to guide strategic partnering activities, capital markets initiatives, and drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
none
-
News

Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders

Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) has announced a transformative licensing transaction with Dr. Reddy's Laboratories (DRL) providing up to $733 MM in non-dilutive upfront payments and potential sales and regulatory milestones. The company also successfully closed a private placement financing of $26.5 MM, anticipating a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
News

Coya Therapeutics Announces Closing of $26.5 Million Private Placement

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) closed a private placement offering of 4,370,382 shares of common stock, raising $26.5 million. Net proceeds are expected to be approximately $24.1 million, intended for general corporate purposes, working capital, and to support preclinical, clinical, and regulatory activities. The financing is anticipated to fund operations into 2026, with participation from former U.S. Secretary of Commerce Wilbur Ross and other existing institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News

Coya Therapeutics Announces $26.5 Million Private Placement

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq:COYA) has entered into definitive securities purchase agreements for the purchase and sale of 4,370,382 shares of its common stock at a purchase price of $6.06 per share in a private placement priced at-the-market under Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Rhea-AI Summary
Dr. Reddy's Laboratories SA (NYSE: RDY) and Coya Therapeutics, Inc. (NASDAQ: COYA) have entered into a development and license agreement for the commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). The agreement grants Dr. Reddy's the exclusive rights to commercialize COYA 302 in the United States, Canada, the European Union, and the United Kingdom. The agreement includes an upfront payment of USD 7.5 million to Coya, with additional milestone payments of up to USD 40 million and sales-based milestone payments of up to USD 677.25 million. Dr. Reddy's will also pay royalties based on a percentage of net sales of COYA 302 ranging from low to middle teens. The development of COYA 302 was a result of a research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
News

Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

Rhea-AI Summary
COYA (Coya Therapeutics, Inc.) announced Q3 2023 financial results and clinical updates, including completion of enrollment in a Phase 2 study for Alzheimer’s Disease, new data for the treatment of Amyotrophic Lateral Sclerosis, and securing licensing rights for Exosome Engineering Technology (EET) from Carnegie Mellon University. The company also published research articles, appointed new board members and clinical advisors, and provided anticipated events and milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings
-
News

Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon

Rhea-AI Summary
Coya Therapeutics announces positive results from a study on Low Dose IL-2 in Alzheimer's patients. A double-blind, placebo-controlled study is fully enrolled and will release data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
clinical trial
-
News

Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Rhea-AI Summary
Coya Therapeutics completes enrollment in phase 2 study of LD IL-2 in patients with mild-to-moderate AD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
clinical trial
News

Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Rhea-AI Summary
Coya Therapeutics announces new experimental data on COYA 302 for ALS treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none

FAQ

What is the current stock price of Coya Therapeutics (COYA)?

The current stock price of Coya Therapeutics (COYA) is $5.24 as of December 20, 2024.

What is the market cap of Coya Therapeutics (COYA)?

The market cap of Coya Therapeutics (COYA) is approximately 86.9M.

What does Coya Therapeutics, Inc. specialize in?

Coya Therapeutics specializes in developing therapies that modulate regulatory T cells (Tregs) for treating neurodegenerative, autoimmune, and metabolic diseases.

What are regulatory T cells (Tregs)?

Regulatory T cells (Tregs) are a type of immune cell that helps maintain immune system balance and prevent autoimmune responses.

What types of diseases is Coya Therapeutics targeting?

The company is targeting neurodegenerative, autoimmune, and metabolic diseases such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

What are the recent achievements of Coya Therapeutics?

Recent achievements include advancements in clinical trials for their Treg therapies, strategic partnerships, and collaborations with leading research institutions.

How is Coya Therapeutics funded?

Coya Therapeutics is supported by a robust financial condition, which includes investments and collaborations with other healthcare organizations.

What is the significance of Treg therapies?

Treg therapies aim to restore immune balance, potentially offering new treatment options for diseases with limited current therapies.

Are there any ongoing clinical trials by Coya Therapeutics?

Yes, Coya Therapeutics is actively engaged in multiple clinical trials to evaluate the safety and efficacy of its Treg-targeted treatments.

Who are Coya Therapeutics' partners?

The company collaborates with leading research institutions and healthcare organizations to advance its therapeutic candidates.

What can investors expect from Coya Therapeutics?

Investors can expect updates on clinical trial progress, new product developments, and potential market launches.

How can I stay updated on Coya Therapeutics' news?

You can stay updated by following their news releases and financial reports for the latest information on achievements and future directions.

Stock COYA logo
Coya Therapeutics, Inc.

Nasdaq:COYA

COYA Rankings

#4511 Ranked by Market Cap
N/A Ranked by Dividends

COYA Stock Data

86.88M
15.04M
7.03%
19.97%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON